LONDON, May 8, 2015 /PRNewswire/ --

Editor Note: For more information about this release, please scroll to bottom.

Investor-Edge has initiated coverage on the following equities: Biocept Inc. (NASDQ: BIOC), Athersys Inc. (NASDAQ: ATHX), Biogen Inc. (NASDAQ: BIIB), Dyax Corporation (NASDAQ: DYAX), and Incyte Corporation (NASDAQ: INCY). Free research report on Biocept can be accessed at http://get.Investor-Edge.com/pdf/?c=Biocept&d=08-May-2015&s=BIOC. The US markets on Thursday, May 07, 2015, ended on a positive note as the Dow Jones Industrial Average finished at 17,924.06, up 0.46% and the NASDAQ Composite closed at 4,945.54, up 0.53%. The S&P 500 finished the session 0.38% higher at 2,088.00. During the trading session, nine out of ten sectors finished on a higher note. The S&P 500 Health Care Sector Index ended the day at 834.99, up 0.47%, with the index advancing 3.49% in the previous three months. Register for your complimentary reports at the links given below.

Biocept Inc.'s stock edged 0.70% higher, to close the day at $2.87. The stock recorded a trading volume of 0.60 million shares, below its three months average volume of 4.33 million shares. The company's shares oscillated between $2.81 and $2.97 during the session. Over the last one month and over the past three months, Biocept Inc.'s shares have surged 21.61% and 36.02%, respectively. Furthermore, the stock has gained 15.73% since the start of this year. The company is trading above its 50-day moving average of $2.78, while the 50-day moving average is below Biocept Inc.'s 200-day moving average of $3.11. Additionally, the stock has a Relative Strength Index (RSI) of 52.76. Sign up and read the free notes on BIOC at:

http://get.Investor-Edge.com/pdf/?c=Biocept&d=08-May-2015&s=BIOC

On Thursday, Athersys Inc.'s stock recorded a trading volume of 1.47 million shares, lower than its three months average volume of 2.14 million shares. The stock ended the day at $1.19, which was 0.83% below its previous day's closing of $1.20, and registered an intraday range of $1.17 and $1.24. Athersys Inc.'s shares have lost 3.25% in the previous three trading sessions, 58.25% in the last one month, and 24.68% on YTD basis. The company is trading below its 50-day and 200-day moving averages of $2.45 and $1.80, respectively. Furthermore, shares of Athersys Inc. have an RSI of 24.62. The complimentary notes on ATHX can be downloaded as in PDF format at:

http://get.Investor-Edge.com/pdf/?c=Athersys&d=08-May-2015&s=ATHX

Biogen Inc.'s stock edged 0.07% lower to end Thursday's session at $383.29. The stock recorded a trading volume of 1.30 million shares, below its three months average volume of 2.00 million shares. The company's shares fluctuated between $380.61 and $388.07 during the session. Shares of the company traded at a PE ratio of 27.93. Biogen Inc.'s shares have gained 12.92% since the beginning of 2015. However, the stock has fallen by 0.76% in the previous three trading sessions and 4.65% over the last three months. The company is trading above its 200-day moving average. Biogen Inc.'s 50-day moving average of $416.89 is above its 200-day moving average of $358.21. Additionally, the stock has an RSI of 37.97. Register for free on Investor-Edge and access the latest research on BIIB at:

http://get.Investor-Edge.com/pdf/?c=Biogen&d=08-May-2015&s=BIIB

On Thursday, shares in Dyax Corp. fluctuated between $24.84 and $26.05 before ending the session 1.17% higher at $25.98. The stock reported a trading volume of 1.43 million shares, lower than its three months average volume of 1.98 million shares. Dyax Corp.'s stock has surged 4.84% in the previous three trading sessions, 72.17% in the last one month, and 84.78% on YTD basis. The company is trading above its 50-day and 200-day moving averages of $21.86 and $14.64, respectively. Moreover, shares of Dyax Corp. have an RSI of 53.44. The complete research on DYAX is available for free at:

http://get.Investor-Edge.com/pdf/?c=Dyax%20Corp.&d=08-May-2015&s=DYAX

Incyte Corp.'s stock finished Thursday's session 1.53% higher at $102.08. A total of 1.20 million shares were traded, which was below its three months average volume of 1.22 million shares. The stock vacillated between $100.32 and $103.64 during the session. Over the last one month and over the past three months, Incyte Corp.'s shares have surged 14.20% and 35.47%, respectively. Additionally, from the beginning of 2015, the stock has rallied 39.63%. The company's shares are trading above their 50-day and 200-day moving averages. Moreover, the stock's 50-day moving average of $94.81 is greater than its 200-day moving average of $70.95. Incyte Corp.'s stock has an RSI of 53.25. Free in depth research on INCY is available at:

http://get.Investor-Edge.com/pdf/?c=Incyte&d=08-May-2015&s=INCY

About Investor-Edge.com

At Investor-Edge, we provide our members with a simple and reliable way to leverage our economy of scale. Most investors do not have time to track all publicly traded companies, much less perform an in-depth review and analysis of the complexities contained in each situation. That's where Investor-Edge comes in. We provide a single unified platform for investors' to hear about what matters. Situation alerts, moving events, and upcoming opportunities.

===============

EDITOR'S NOTES:

===============

1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.

2. Information in this release is produced on a best efforts basis. The content is then further fact checked and reviewed by an outsourced research provider. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.

3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.

4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] www.investor-edge.com.

5. For any urgent concerns or inquiries, please contact us at compliance [at] www.investor-edge.com.

6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] www.investor-edge.com for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Investor-Edge. An outsourced research services provider, represented by a registered analyst has only reviewed the information provided by Investor-Edge in this article or report according to the procedures outlined by Investor-Edge. Investor-Edge is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE

Investor-Edge makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Investor-Edge is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Investor-Edge whatsoever for any direct, indirect or consequential loss arising from the use of this document. Investor-Edge expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Investor-Edge does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

CFA(R) and Chartered Financial Analyst(R) are registered trademarks owned by CFA Institute.

SOURCE Investor-Edge